Adjuvant chemotherapy for soft tissue sarcoma

Paolo G. Casali, Piero Picci

Research output: Contribution to journalArticle

Abstract

Purpose of review: To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas. Recent findings: Most recent contributions have added nonrandomized evidence to previously available controlled clinical trials, which were undertaken from the 1970s. Again, results are conflicting, with a limited benefit suggested by some retrospective analyses and denied by others. While a delay in relapse is likely to occur in a fraction of patients treated with adjuvant chemotherapy, a permanent benefit has been more difficult to prove. This result is consistent with findings from previous clinical trials, which pointed to a slight benefit from Doxorubicin-based adjuvant chemotherapy and a possibly higher, although less evidence-based, benefit from anthracycline plus Ifosfamide regimens. Summary: Overall, adjuvant chemotherapy may give some benefit in soft tissue sarcoma. If any, it is likely to be of limited degree, confined to the highest-risk patients, and requiring a fully active chemotherapy regimen. This was mainly shown for extremity soft tissue sarcoma but may also apply to other primary sites. The value of molecular-targeted therapy as an adjuvant for high-risk gastrointestinal stromal tumor patients is a different subject awaiting long-term results of ongoing trials.

Original languageEnglish
Pages (from-to)361-365
Number of pages5
JournalCurrent Opinion in Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Adjuvant Chemotherapy
Sarcoma
Molecular Targeted Therapy
Ifosfamide
Gastrointestinal Stromal Tumors
Anthracyclines
Controlled Clinical Trials
Doxorubicin
Extremities
Clinical Trials
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Adjuvant therapy
  • Chemotherapy
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Adjuvant chemotherapy for soft tissue sarcoma. / Casali, Paolo G.; Picci, Piero.

In: Current Opinion in Oncology, Vol. 17, No. 4, 07.2005, p. 361-365.

Research output: Contribution to journalArticle

Casali, Paolo G. ; Picci, Piero. / Adjuvant chemotherapy for soft tissue sarcoma. In: Current Opinion in Oncology. 2005 ; Vol. 17, No. 4. pp. 361-365.
@article{b9630e906320422fbcb6a6a0b4cbba49,
title = "Adjuvant chemotherapy for soft tissue sarcoma",
abstract = "Purpose of review: To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas. Recent findings: Most recent contributions have added nonrandomized evidence to previously available controlled clinical trials, which were undertaken from the 1970s. Again, results are conflicting, with a limited benefit suggested by some retrospective analyses and denied by others. While a delay in relapse is likely to occur in a fraction of patients treated with adjuvant chemotherapy, a permanent benefit has been more difficult to prove. This result is consistent with findings from previous clinical trials, which pointed to a slight benefit from Doxorubicin-based adjuvant chemotherapy and a possibly higher, although less evidence-based, benefit from anthracycline plus Ifosfamide regimens. Summary: Overall, adjuvant chemotherapy may give some benefit in soft tissue sarcoma. If any, it is likely to be of limited degree, confined to the highest-risk patients, and requiring a fully active chemotherapy regimen. This was mainly shown for extremity soft tissue sarcoma but may also apply to other primary sites. The value of molecular-targeted therapy as an adjuvant for high-risk gastrointestinal stromal tumor patients is a different subject awaiting long-term results of ongoing trials.",
keywords = "Adjuvant therapy, Chemotherapy, Soft tissue sarcoma",
author = "Casali, {Paolo G.} and Piero Picci",
year = "2005",
month = "7",
doi = "10.1097/01.cco.0000166652.15546.4f",
language = "English",
volume = "17",
pages = "361--365",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Adjuvant chemotherapy for soft tissue sarcoma

AU - Casali, Paolo G.

AU - Picci, Piero

PY - 2005/7

Y1 - 2005/7

N2 - Purpose of review: To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas. Recent findings: Most recent contributions have added nonrandomized evidence to previously available controlled clinical trials, which were undertaken from the 1970s. Again, results are conflicting, with a limited benefit suggested by some retrospective analyses and denied by others. While a delay in relapse is likely to occur in a fraction of patients treated with adjuvant chemotherapy, a permanent benefit has been more difficult to prove. This result is consistent with findings from previous clinical trials, which pointed to a slight benefit from Doxorubicin-based adjuvant chemotherapy and a possibly higher, although less evidence-based, benefit from anthracycline plus Ifosfamide regimens. Summary: Overall, adjuvant chemotherapy may give some benefit in soft tissue sarcoma. If any, it is likely to be of limited degree, confined to the highest-risk patients, and requiring a fully active chemotherapy regimen. This was mainly shown for extremity soft tissue sarcoma but may also apply to other primary sites. The value of molecular-targeted therapy as an adjuvant for high-risk gastrointestinal stromal tumor patients is a different subject awaiting long-term results of ongoing trials.

AB - Purpose of review: To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas. Recent findings: Most recent contributions have added nonrandomized evidence to previously available controlled clinical trials, which were undertaken from the 1970s. Again, results are conflicting, with a limited benefit suggested by some retrospective analyses and denied by others. While a delay in relapse is likely to occur in a fraction of patients treated with adjuvant chemotherapy, a permanent benefit has been more difficult to prove. This result is consistent with findings from previous clinical trials, which pointed to a slight benefit from Doxorubicin-based adjuvant chemotherapy and a possibly higher, although less evidence-based, benefit from anthracycline plus Ifosfamide regimens. Summary: Overall, adjuvant chemotherapy may give some benefit in soft tissue sarcoma. If any, it is likely to be of limited degree, confined to the highest-risk patients, and requiring a fully active chemotherapy regimen. This was mainly shown for extremity soft tissue sarcoma but may also apply to other primary sites. The value of molecular-targeted therapy as an adjuvant for high-risk gastrointestinal stromal tumor patients is a different subject awaiting long-term results of ongoing trials.

KW - Adjuvant therapy

KW - Chemotherapy

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=21344440027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344440027&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000166652.15546.4f

DO - 10.1097/01.cco.0000166652.15546.4f

M3 - Article

C2 - 15933469

AN - SCOPUS:21344440027

VL - 17

SP - 361

EP - 365

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -